Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer

- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Non Small Cell Lung Cancer
Lung Cancer, Nonsmall Cell
Non Small Cell Lung Cancer Metastatic

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Nintedanib

First Posted Date: 2017-12-19

Last Posted Date: 2024-06-26

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 68

Registration Number: NCT03377023

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Phase 1

Completed

Conditions: Colorectal Cancer
Colorectal Neoplasm
Colorectal Tumors
Colorectal Carcinoma

Interventions: Biological: Nivolumab
Drug: Regorafenib
Drug: Trametinib
Biological: Ipilimumab

First Posted Date: 2017-12-19

Last Posted Date: 2024-12-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 325

Registration Number: NCT03377361

Locations: 🇺🇸
Local Institution - 0111, Miami, Florida, United States
🇨🇱
Local Institution - 0118, Santiago, Región Metropolitana De Santiago, Chile
🇺🇸
Local Institution - 0002, Madison, Wisconsin, United States

and more 44 locations

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Biological: Nivolumab
Biological: BMS-986249
Biological: Ipilimumab

First Posted Date: 2017-12-11

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 607

Registration Number: NCT03369223

Locations: 🇦🇺
Local Institution - 0025, Frankston, Victoria, Australia
🇨🇦
Local Institution - 0056, Ottawa, Ontario, Canada
🇮🇹
Local Institution - 0020, Napoli, Italy

and more 42 locations

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

Phase 2

Completed

Conditions: MGMT-unmethylated Glioblastoma (GBM)
GBM

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Radiation: Radiation Therapy (RT)

First Posted Date: 2017-12-11

Last Posted Date: 2022-07-01

Lead Sponsor: NYU Langone Health

Target Recruit Count: 10

Registration Number: NCT03367715

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Extra Renal Origin
Primary Peritoneal Carcinoma
Clear Cell Adenocarcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2017-11-29

Last Posted Date: 2024-11-25

Lead Sponsor: Brown University

Target Recruit Count: 46

Registration Number: NCT03355976

Locations: 🇺🇸
University of Illinois Chicago, Chicago, Illinois, United States
🇺🇸
Women & Infants Hospital, Providence, Rhode Island, United States
🇺🇸
The Miriam Hospital, Providence, Rhode Island, United States

and more 1 locations

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: Epacadostat
Drug: Nivolumab
Drug: Ipilimumab
Drug: Lirilumab

First Posted Date: 2017-11-20

Last Posted Date: 2022-02-28

Lead Sponsor: Incyte Corporation

Target Recruit Count: 11

Registration Number: NCT03347123

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 2 locations

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Phase 2

Recruiting

Conditions: Melanoma Stage Iv

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Other: Salvage therapy
Radiation: Stereotactic Radiotherapy

First Posted Date: 2017-11-13

Last Posted Date: 2023-11-01

Lead Sponsor: Melanoma Institute Australia

Target Recruit Count: 218

Registration Number: NCT03340129

Locations: 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

and more 5 locations

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Phase 2

Active, not recruiting

Conditions: Genitourinary Cancer
Adrenocortical Carcinoma
Non-urothelial Bladder
Non-urothelial Upper Tract
Penile Cancer
Non-adenocarcinoma Prostate Cancer
Refractory Germ-cell
High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2017-11-07

Last Posted Date: 2024-02-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT03333616

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
University of California, San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations